Home' Australian Pharmacist : Australian Pharmacist October 2015 Contents Australian Pharmacist October 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
options for hyperglycaemia may risk
a more blinkered focus on this aspect
than is desirable. It is pertinent to reflect
that we sometimes chase ever-tighter
control of hyperglycaemia with relatively
unproven therapies, while control
of blood pressure and lipids remains
suboptimal despite the availability of
treatments supported by more robust
clinical outcome data.
As well as lowering BGLs effectively,
the GLP-1 agonists possess a number of
other desirable attributes, in particular
a tendency to reduce appetite,
cause weight loss and carry a low risk
of hypoglycaemia. This contrasts with a
number of other therapies used in type
2 diabetes, such as the sulfonylureas,
thiazolidinediones, and insulin.
They nonetheless share with insulin the
need for administration by subcutaneous
injection, and a high incidence of initial
nausea and vomiting may deter some
patients from persisting with treatment.
Whilst there remains a lack of evidence
showing that GLP-1 agonists lead
to improved clinical outcomes,
they provide a potentially useful option
for controlling hyperglycaemia and
weight in those with type 2 diabetes
who cannot be managed with the more
1. Diabetes Australia. Diabetes in Australia. 2015. At: www.
2. Prins JB. Incretin mimetics and enhancers:
mechanisms of action. Aust Prescr 2008;31:102–4 . At:
3. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review
of head-to-head clinical studies. Ther Adv Endocrinol Metab
4. Electronic Medicines Compendium (UK). Leatherhead, UK:
Datapharm; 2015. At: www.medicines.org.uk/emc
5. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2015.
6. Australian Government Department of Health. Pharmaceutical
Benefits Scheme. 2015. At: www.pbs.gov.au/pbs/home
7. Australian Government Department of Health. Therapeutic
Goods Administration. Australian Register of Therapeutic
Goods. 2015. At: www.tga.gov.au/australian-register-
8. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide
analogues for type 2 diabetes mellitus. Cochrane Database of
Systematic Reviews 2011, Issue 10. Art. No.: CD006423. DOI:
9. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and
safety of dulaglutide versus sitagliptin after 52 weeks in type
2 diabetes in a randomized trial (AWARD-5). Diabetes Care
10. Weissman PN, Carr MC, Ye, J et al. HARMONY 4: randomised
clinical trial comparing once-weekly albiglutide and
insulin glargine in patients in type 2 diabetes inadequately
controlled with metformin with or without sulfonylurea.
11. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily
exenatide in basal insulin-treated patients with type 2
diabetes: a randomized, controlled trial. Ann Intern Med
12. Buse JB, Visboll T, Thurman J, et al. Contribution of liraglutide
in the fixed-ratio combination of insulin degludec and
liraglutide (IDegLira). Diabetes Care 2014;37(11):2926–33 .
13. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits
sustained glycaemic control and progressive reduction of
body weight in patients with type 2 diabetes inadequately
controlled by sulphonylureas with or without metformin.
Diabetes Metab Res Rev 2006;22(6):483–91.
14. Ratner RE, Maggs D, Neilsen LL, et al. Long-term effects of
exenatide therapy over 82 weeks on glycaemic control and
weight in over-weight metformin-treated patients with type
2 diabetes mellitus. Diabetes Obes Metab 2006;8(4):419–28.
15. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily
versus glimepiride for prevention of glycaemic deterioration
in patients with type 2 diabetes with metformin failure
(EUREXA): an open-label, randomised controlled trial. Lancet
16. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly
versus twice daily for the treatment of type 2 diabetes:
a randomised, open-label, non-inferiority study. Lancet
1. Glucagon-like peptide-1 (GLP-1)
is secreted by which ONE of the
following cell types?
a) Pancreatic alpha cells.
b) Ileal and colonic L cells.
c) Pancreatic beta cells.
d) Duodenal K cells.
2. Which ONE of the following is NOT
an effect of the GLP-1 agonists?
a) Delayed gastric emptying.
b) Glucose-dependent stimulation of
c) Inhibition of the enzyme DPP-4.
d) Supressing high glucagon levels.
3. Which ONE of the following has NOT
yet been demonstrated with the
a) Improved clinical outcomes.
b) Reduction in glycosylated haemoglobin
c) Weight loss.
d) Reduction in blood glucose levels
4. When counselling patients
commencing a GLP-1 agonist, which
ONE of the following advice points
regarding adverse effects is LEAST
a) If nausea and vomiting occur with
the first few doses, you should cease
b) If you experience severe, persistent
abdominal pain with treatment you
should consult your doctor.
c) Initial treatment is with a low dose to
help reduce the risk of side effects, but
the dose may be increased later if you
d) If using with a sulfonylurea (e.g.
gliclazide), you should remain alert to
the possibility of hypoglycaemia.
5. The combination of exenatide with
which ONE of the following is NOT
approved by the TGA?
b) Glimepiride (a sulfonylurea).
c) Insulin glargine.
d) Vildagliptin (a DPP-4 inhibitor).
17. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day
versus exenatide twice a day for type 2 diabetes: a 26-week
randomised, parallel-group, multinational, open-label trial
(LEAD-6). Lancet 2009;374(9683):39–47.
18. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of
dulaglutide added onto pioglitazone and metformin versus
exenatide in type 2 diabetes in a randomized controlled trial
(AWARD-1). Diabetes Care 2014; 37(8): 2159–67.
19. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-
like peptide-1 receptor agonists on weight loss: systematic
review and meta-analyses of randomised controlled trials.
20. Ottney A. Glucagon-like peptide-1 receptor agonists for
weight loss in adult patients without diabetes. Am J Health
Syst Pharm 2013;70(23):2097–103.
21. US Food and Drug Administration (FDA). FDA news
release: FDA approves weight-management drug
Saxenda. 2014. At: www.fda.gov/NewsEvents/Newsroom/
22. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal
insulin replacement in type 2 diabetes inadequately
controlled with insulin glargine plus oral agents: a
comparison of adding albiglutide, a weekly GLP-1 receptor
agonist, versus thrice-daily prandial insulin lispro. Diabetes
23. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly
versus liraglutide once daily in patients with type 2 diabetes
(DURATION-6): a randomised, open-label study. Lancet
24. Pratley RE, Nauck MA, Barnett AH et al. Once-weekly
albiglutide versus once-daily liraglutide in patients with type
2 diabetes inadequately controlled on oral drugs (HARMONY
7): a randomised, open-label, multicentre, non-inferiority
phase 3 study. Lancet Diabetes Endocrinol 2014;2(4):289–97.
25. Reutens AT, Shaw JE. Incretin mimetics and enhancers:
clinical applications. Aust Prescr 2008;31:104–8. At:
26. Singh S, Chang HY, Richard TM, et al. Glucagon-like peptide
1-based therapies and risk of hospitalization for acute
pancreatitis in type 2 diabetes mellitus: a population-
based matched case-control study. JAMA Intern Med
27. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of
incretin-based drugs--FDA and EMA assessment. NEJM
28. NPS MedicineWise. Incretins and pancreatitis — is there a
problem? In: NPS Health news and evidence. 2013. At: www.
Links Archive Australian Pharmacist September 2015 Australian Pharmacist November 2015 Navigation Previous Page Next Page